Modelling the natural history of Huntington's disease progression

被引:13
作者
Kuan, W. L. [1 ]
Kasis, A. [2 ]
Yuan, Y. [2 ]
Mason, S. L. [1 ]
Lazar, A. S. [1 ]
Barker, R. A. [1 ]
Goncalves, J. [2 ,3 ]
机构
[1] Univ Cambridge, Dept Clin Neurosci, John van Geest Ctr Brain Repair, Cambridge, England
[2] Univ Cambridge, Dept Engn, Cambridge CB2 1PZ, England
[3] Univ Luxembourg, Luxembourg Ctr Syst Biomed, Walferdange, Belval, Luxembourg
基金
英国工程与自然科学研究理事会;
关键词
CAG-REPEAT LENGTH; AGE-OF-ONSET; NEURODEGENERATIVE DISEASES; CLINICAL PROGRESSION; RATING-SCALE;
D O I
10.1136/jnnp-2014-308153
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background The lack of reliable biomarkers to track disease progression is a major problem in clinical research of chronic neurological disorders. Using Huntington's disease (HD) as an example, we describe a novel approach to model HD and show that the progression of a neurological disorder can be predicted for individual patients. Methods Starting with an initial cohort of 343 patients with HD that we have followed since 1995, we used data from 68 patients that satisfied our filtering criteria to model disease progression, based on the Unified Huntington's Disease Rating Scale (UHDRS), a measure that is routinely used in HD clinics worldwide. Results Our model was validated by: (A) extrapolating our equation to model the age of disease onset, (B) testing it on a second patient data set by loosening our filtering criteria, (C) cross-validating with a repeated random subsampling approach and (D) holdout validating with the latest clinical assessment data from the same cohort of patients. With UHDRS scores from the past four clinical visits (over a minimum span of 2 years), our model predicts disease progression of individual patients over the next 2 years with an accuracy of 89-91%. We have also provided evidence that patients with similar baseline clinical profiles can exhibit very different trajectories of disease progression. Conclusions This new model therefore has important implications for HD research, most obviously in the development of potential disease-modifying therapies. We believe that a similar approach can also be adapted to model disease progression in other chronic neurological disorders.
引用
收藏
页码:1143 / 1149
页数:7
相关论文
共 50 条
[11]   mHTT Seeding Activity: A Marker of Disease Progression and Neurotoxicity in Models of Huntington's Disease [J].
Ast, Anne ;
Buntru, Alexander ;
Schindler, Franziska ;
Hasenkopf, Regine ;
Schulz, Aline ;
Brusendorf, Lydia ;
Klockmeier, Konrad ;
Grelle, Gerlinde ;
McMahon, Benjamin ;
Niederlechner, Hannah ;
Jansen, Isabelle ;
Diez, Lisa ;
Edel, Juliane ;
Boeddrich, Annett ;
Franklin, Sophie A. ;
Baldo, Barbara ;
Schnoegl, Sigrid ;
Kunz, Severine ;
Purfuerst, Bettina ;
Gaertner, Annette ;
Kampinga, Harm H. ;
Morton, A. Jennifer ;
Petersen, Asa ;
Kirstein, Janine ;
Bates, Gillian P. ;
Wanker, Erich E. .
MOLECULAR CELL, 2018, 71 (05) :675-+
[12]   Indexing Disease Progression at Study Entry With Individuals At-Risk for Huntington Disease [J].
Zhang, Ying ;
Long, Jeffrey D. ;
Mills, James A. ;
Warner, John H. ;
Lu, Wenjing ;
Paulsen, Jane S. .
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2011, 156B (07) :751-763
[13]   HIV/hepatitis C coinfection natural history and disease progression [J].
Hernandez, Maria D. ;
Sherman, Kenneth E. .
CURRENT OPINION IN HIV AND AIDS, 2011, 6 (06) :478-482
[14]   The role of immunity in Huntington's disease [J].
Soulet, D. ;
Cicchetti, F. .
MOLECULAR PSYCHIATRY, 2011, 16 (09) :889-902
[15]   GENETICS AND NEUROPATHOLOGY OF HUNTINGTON'S DISEASE [J].
Reiner, Anton ;
Dragatsis, Ioannis ;
Dietrich, Paula .
PATHOPHYSIOLOGY, PHARMACOLOGY, AND BIOCHEMISTRY OF DYSKINESIA, 2011, 98 :325-372
[16]   Modeling Disease Progression and Placebo Response in Huntington Disease [J].
Boareto, Marcelo ;
Yamamoto, Yumi ;
Long, Jeffrey D. ;
Sampaio, Cristina ;
McColgan, Peter ;
Diack, Cheikh ;
Ducray, Patricia Sanwald .
NEUROLOGY, 2025, 104 (10)
[17]   A Tale of Two Factors: What Determines the Rate of Progression in Huntington's Disease? A Longitudinal MRI Study [J].
Rosas, H. Diana ;
Reuter, Martin ;
Doros, Gheorghe ;
Lee, Stephanie Y. ;
Triggs, Tyler ;
Malarick, Keith ;
Fischl, Bruce ;
Salat, David H. ;
Hersch, Steven M. .
MOVEMENT DISORDERS, 2011, 26 (09) :1691-1697
[18]   Topoisomerase 1 inhibitor topotecan delays the disease progression in a mouse model of Huntington's disease [J].
Shekhar, Shashi ;
Vatsa, Naman ;
Kumar, Vipendra ;
Singh, Brijesh Kumar ;
Jamal, Imran ;
Sharma, Ankit ;
Jana, Nihar Ranjan .
HUMAN MOLECULAR GENETICS, 2017, 26 (02) :420-429
[19]   Huntington's disease [J].
Ha, Ainhi D. ;
Fung, Victor S. C. .
CURRENT OPINION IN NEUROLOGY, 2012, 25 (04) :491-498
[20]   Huntington's Disease [J].
Finkbeiner, Steven .
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2011, 3 (06) :1-24